Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
RecruitingPhase 2
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
About the study
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
What is being tested
- Gen 2 Travoprost Intracameral Implant (drug)
- Timolol eye drops 0.5% (drug)
- Sham Procedure (procedure)
- Placebo eye drops (other)
Sponsor: Glaukos Corporation · Participants: 110 · Started: Jun 12, 2025
Contact the study team
- Study Director · Phone: 949-739-8749
Official record on ClinicalTrials.gov — NCT07075718
Locations in the U.S.
| Colorado | Glaukos Investigative Site, Grand Junction |
| Oklahoma | Glaukos Investigative Site, Oklahoma City |
| Texas | Glaukos Clinical Site, El Paso |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.